The CAR-T Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“CAR-T Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CAR-T Market.
Some of the key takeaways from the CAR-T Pipeline Report:
- Companies across the globe are diligently working toward developing novel CAR-T treatment therapies with a considerable amount of success over the years.
- CAR-T companies working in the treatment market are Sana Biotechnology, CRISPR Therapeutics, Verismo Therapeutics, EXUMA BIOTECHNOLOGY, Autolus Limited, Carsgen Therapeutics, Tessa Therapeutics, Cartesian Therapeutics, Miltenyi Biomedicine, autoleucel CARsgen, CASI Pharmaceuticals, IASO Biotherapeutics, and others, are developing therapies for the CAR-T treatment
- Emerging CAR-T therapies in the different phases of clinical trials are- SG295, CTX110, SynKIR 110, CCT3-AXL-0038, AUTO4, CAR-GPC3, TT11, Descartes-08, MB-CART2019.1, Zevorcabtagene, CNCT19, CT 103A, and others are expected to have a significant impact on the CAR-T market in the coming years.
- In December 2022, IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company specialising in the discovery, development, and production of novel cell therapies and antibody products, announced that the U.S. Food and Drug Administration (FDA) had approved the IND application for its BCMA CAR-T CT103A (equecabtagene autoleucel) therapy
- In June 2022, The new drug application (NDA) for InnoVent and IASO Biotherapeutics’ Equecabtagene Autoleucel to treat relapsed and/or refractory multiple myeloma (R/R MM) has been approved by the China National Medical Products Administration (NMPA)
- On January 10, 2022 Sana Biotechnology and Innovent Biologics have announced that they have entered into an agreement under which Sana has been granted non-exclusive commercial rights to a fully human BCMA CAR construct that has been clinically validated for use in ex vivo and in vivo applications for gene therapy and immunotherapy
- In April 2020, To assess the effectiveness and safety of CT103A in patients with relapsed and refractory MM, IASO Biotherapeutics started a single-armed, open-label, multicenter Phase I/II research. To create T cells with the CT103A chimeric antigen receptor (CAR) modification, leukapheresis will be used
CAR-T Overview
CAR-T cells are the fusion proteins comprising one or more intracellular signalling domains of the T-cell receptor and one or more single-chain fragments from a particular monoclonal antibody. A CAR combines antigen-binding domains, most frequently a single-chain variable fragment (scFv) made from the variable domains of antibodies, with the TCR chain’s signalling domains and extra costimulatory domains from receptors like CD28, OX40, and CD137.
Get a Free Sample PDF Report to know more about CAR-T Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/car-t-pipeline-insight
Emerging CAR-T Drugs Under Different Phases of Clinical Development Include:
- SG295: Sana Biotechnology
- CTX110: CRISPR Therapeutics
- SynKIR 110: Verismo Therapeutics
- CCT3-AXL-0038: EXUMA BIOTECHNOLOGY
- AUTO4: Autolus Limited
- CAR-GPC3: Carsgen Therapeutics
- TT11: Tessa Therapeutics
- Descartes-08: Cartesian Therapeutics
- MB-CART2019.1: Miltenyi Biomedicine
- Zevorcabtagene: autoleucel CARsgen
- CNCT19: CASI Pharmaceuticalsf
- CT 103A: IASO Biotherapeutics
- CTL119: Novartis
- CD19-targeted CAR-T cells: Sinobioway Cell Therapy
- EPCAM-targeted CAR T-cells: Sinobioway Cell Therapy
CAR-T Route of Administration
CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intravenous
- Intramuscular
- Subcutaneous
- Intratumoral
- Mechanism of Action
CAR-T Molecule Type
CAR-T Products have been categorized under various Molecule types, such as
- T lymphocyte replacements
- Immunologic cytotoxicity
- Product Type
CAR-T Pipeline Therapeutics Assessment
- CAR-T Assessment by Product Type
- CAR-T By Stage and Product Type
- CAR-T Assessment by Route of Administration
- CAR-T By Stage and Route of Administration
- CAR-T Assessment by Molecule Type
- CAR-T by Stage and Molecule Type
DelveInsight’s CAR-T Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further CAR-T product details are provided in the report. Download the CAR-T pipeline report to learn more about the emerging CAR-T therapies
Some of the key companies in the CAR-T Therapeutics Market include:
Key companies developing therapies for CAR-T are – AbbVie Inc., Adaptimmune Therapeutics PLC., Amgen, Inc., Atara Biotherapeutics, Inc., Aurora Biopharma, Inc., Autolus Therapeutics PLC., Bellicum Pharmaceuticals, Inc., BioAtla LLC., bluebird bio, Carina Biotech, CARsgen Therapeutics, Ltd., CARTherics, Celgene, Cellectis, Celularity, Celyad SA, Creative Biolabs, DiaCarta, Inc., Endocyte, Inc., F1 Oncology, Inc., Fate Therapeutics Inc., Gilead, Humanigen, Inc., Immune Therapeutics, Inc., Intrexon, Corp., Juno Therapeutics, Inc., Kite Pharma, Inc., Lion TCR Pte Ltd., MaxCyte, Inc., Mesoblast, Ltd., Minerva Biotechnologies Corp., Mustang Bio, Inc., Novartis AG, Oxford BioMedica PLC., PeproMene Bio Inc., Pfizer, Inc., Posedia Therapeutics Inc., Precision Biosciences, Inc., ProMab Biotechnologies Inc., Servier Oncology, Sorrento Therapeutics, Inc., TC Biopharm Ltd., Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Tmunity Therapeutics Inc., TrakCel Ltd., Xyphos, ZIOPHARM Oncology, Inc., and others.
CAR-T Pipeline Analysis:
The CAR-T pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of CAR-T with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR-T Treatment.
- CAR-T key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- CAR-T Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR-T market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about CAR-T drugs and therapies
CAR-T Pipeline Market Drivers
- Increased Collaborations and Acquisitions, wide range of targets and indications, increased clinical and preclinical studies with positive results are some of the important factors that are fueling the CAR-T Market.
CAR-T Pipeline Market Barriers
- However, scalability and cost to ensure accessibility and affordability, technological barriers, optimization of dosing and toxicity concerns and other factors are creating obstacles in the CAR-T Market growth.
Scope of CAR-T Pipeline Drug Insight
- Coverage: Global
- Key CAR-T Companies: Sana Biotechnology, CRISPR Therapeutics, Verismo Therapeutics, EXUMA BIOTECHNOLOGY, Autolus Limited, Carsgen Therapeutics, Tessa Therapeutics, Cartesian Therapeutics, Miltenyi Biomedicine, autoleucel CARsgen, CASI Pharmaceuticals, IASO Biotherapeutics, and others
- Key CAR-T Therapies: SG295, CTX110, SynKIR 110, CCT3-AXL-0038, AUTO4, CAR-GPC3, TT11, Descartes-08, MB-CART2019.1, Zevorcabtagene, CNCT19, CT 103A, and others
- CAR-T Therapeutic Assessment: CAR-T current marketed and CAR-T emerging therapies
- CAR-T Market Dynamics: CAR-T market drivers and CAR-T market barriers
Request for Sample PDF Report for CAR-T Pipeline Assessment and clinical trials
Table of Contents
1. CAR-T Report Introduction
2. CAR-T Executive Summary
3. CAR-T Overview
4. CAR-T- Analytical Perspective In-depth Commercial Assessment
5. CAR-T Pipeline Therapeutics
6. CAR-T Late Stage Products (Phase II/III)
7. CAR-T Mid Stage Products (Phase II)
8. CAR-T Early Stage Products (Phase I)
9. CAR-T Preclinical Stage Products
10. CAR-T Therapeutics Assessment
11. CAR-T Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. CAR-T Key Companies
14. CAR-T Key Products
15. CAR-T Unmet Needs
16 . CAR-T Market Drivers and Barriers
17. CAR-T Future Perspectives and Conclusion
18. CAR-T Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services